Clinical Trial Update: A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating doxorubicin with olaratumab in advanced or metastatic soft tissue sarcoma has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Doxorubicin (doxorubicin)
• Olaratumab (olaratumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Soft Tissue Sarcoma | Phase 3 | Status: COMPLETED | Results posted: 2019-12-17